How does VEOZAH work?
Unlike anything else, VEOZAH directly blocks a source of hot flashes and night sweats. It works in your hypothalamus—the area of your brain that controls body temperature.
For moderate to severe Vasomotor Symptoms (VMS) due to menopause
For moderate to severe Vasomotor Symptoms (VMS) due to menopause
What’s VEOZAH?
VEOZAH (fezolinetant) is an FDA-approved prescription treatment for moderate to severe VMS (Vasomotor Symptoms)—also known as hot flashes and night sweats due to menopause.
Science has revealed that VMS—also known as Vasomotor Symptoms—the medical name for hot flashes and night sweats—due to menopause isn't caused by declining estrogen alone.
In fact, we know that a brain chemical called neurokinin B, or NKB for short, is a trigger of VMS. NKB is found in the temperature control center of your brain, the hypothalamus.
When NKB binds to the receptor in the hypothalamus during menopause it triggers hot flashes and night sweats.
VEOZAH is the first prescription treatment of its kind for moderate to severe Vasomotor Symptom (VMS) due to menopause.
VEOZAH is designed to directly block NKB from binding to the receptor. This reduces hot flashes and night sweats due to menopause.
Please see Important Safety Information during this video or on the website below.
VEOZAH is the first and only prescription treatment designed to specifically block neurokinin B (NKB). NKB is a chemical that binds to a receptor in your brain, triggering hot flashes and night sweats due to menopause.
What can VEOZAH do to help you?
Here are a few reasons to talk to your doctor:
*Based on clinical studies measuring efficacy at 4 and 12 weeks.
Starting the conversation with your doctor
VMS is a real medical condition worth talking about, so let's get talking!
Take this quick quiz to help you get the treatment conversation started with your doctor.
- Answer 8 questions about the impact of hot flashes.
- Save or print your personalized Doctor Discussion Guide.
- Use your personalized Doctor Discussion Guide to help start a conversation about VMS treatment options with your healthcare provider.
Don’t have time to take the quiz now? Download the Doctor Discussion Guide.
What are the possible side effects of VEOZAH?
- Do not use VEOZAH if you have cirrhosis, severe kidney problems, or kidney failure.
- Do not use VEOZAH if you are taking certain medicines called CYP1A2 inhibitors. Ask your healthcare provider if you are not sure.
- VEOZAH can cause serious side effects, including increased liver blood test values and liver problems. Your healthcare provider will do a blood test to check your liver before you start taking VEOZAH. Your healthcare provider will also do this blood test monthly for the first 3 months, at month 6, and month 9 after you start taking VEOZAH or if you have signs or symptoms that suggest liver problems. If your liver blood test values are elevated, your healthcare provider may advise you to stop treatment or request additional liver blood tests.
- Stop VEOZAH and call your healthcare provider right away if you have the following signs or symptoms of liver problems: feeling more tired than you do usually, nausea, vomiting, itching, yellowing of the eyes or skin (jaundice), pale feces, dark urine, or pain in the upper right stomach (abdomen).
- The most common side effects of VEOZAH are stomach (abdominal) pain, diarrhea, difficulty sleeping (insomnia), back pain, and hot flashes or hot flushes.
While taking VEOZAH, its important to keep your doctor informed. This gives them valuable insights along your treatment journey.
<p></p>
IMPORTANT SAFETY INFORMATION
Do not use VEOZAH if you:
- have cirrhosis.
- have severe kidney problems or kidney failure.
- are taking certain medicines called CYP1A2 inhibitors. Ask your healthcare provider if you are not sure.
What is VEOZAH™ (fezolinetant)?
VEOZAH is a prescription medicine used to reduce moderate to severe vasomotor symptoms due to menopause. VEOZAH is not a hormone. Vasomotor symptoms are the feelings of warmth in the face, neck, and chest, or sudden intense feelings of heat and sweating (“hot flashes” or “hot flushes”).
Before you use VEOZAH, tell your healthcare provider about all of your medical conditions, including if you:
- have liver disease or problems.
- have kidney problems.
- have any medical conditions that may become worse while you are using VEOZAH.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VEOZAH may affect the way other medicines work, and other medicines may affect how VEOZAH works.
VEOZAH can cause serious side effects, including:
- increased liver blood test values and liver problems. Your healthcare provider will do a blood test to check your liver before you start taking VEOZAH. Your healthcare provider will also do this blood test monthly for the first 3 months, at month 6, and month 9 after you start taking VEOZAH or if you have signs or symptoms that suggest liver problems. If your liver blood test values are elevated, your healthcare provider may advise you to stop treatment or request additional liver blood tests.
Stop VEOZAH and call your healthcare provider right away if you have the following signs or symptoms of liver problems:
- feeling more tired than you do usually
- nausea
- vomiting
- itching
- yellowing of the eyes or skin (jaundice)
- pale feces
- dark urine
- pain in the right upper stomach (abdomen)
The most common side effects of VEOZAH include:
- stomach (abdominal) pain
- diarrhea
- difficulty sleeping (insomnia)
- back pain
- hot flashes or hot flushes
These are not all the possible side effects of VEOZAH. Tell your healthcare provider if you have any side effect that bothers you or does not go away.
Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
For more information, talk to your healthcare provider and see Patient Product Information for VEOZAH (fezolinetant).
